Comparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis.
Journal
Clinical & experimental ophthalmology
Journal Volume
53
Journal Issue
1
Start Page
39
End Page
53
ISSN
1442-9071
Date Issued
2025
Author(s)
Yang, Ting-Kai
Kuo, Hou-Ting
Ju, Yuh-Jen
Chen, Chun-Yi
Chen, Wen-Hsien
Wu, Albert Y
Lin, Chun-Ju
Ho, Jennifer Hui-Chun
DOI
10.1111/ceo.14447
Abstract
Background: To evaluate and compare the long-term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. ‘Long-term’ is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs). Methods: This systematic review and model-based network meta-analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs. Patients with NTG were selected based on strict inclusion/exclusion criteria, with randomsation procedures and masking as reported in the individual trials. Eight different medications were compared, including prostaglandin analogues, beta-blockers, brimonidine, unoprostone isopropyl, brovincamine, and palmitoylethanolamide (PEA). Notably, PEA is an oral medication, while other drugs are topical agents. Results: Primary outcome is the long-term efficacy of IOP control across medications with different follow-up durations. Among the eight medications, PEA demonstrates the highest efficacy (Surface under the cumulative ranking, SUCRA = 7.46%), followed by two prostaglandin analogues: travoprost (SUCRA = 6.86%) and latanoprost (SUCRA = 6.76%), then two beta-blockers: nipradilol (SUCRA = 4.90%) and timolol (SUCRA = 4.89%). Both brimonidine and unoprostone isopropyl have SUCRA scores below 4.0%, indicating modest but limited efficacy. Brovincamine has the lowest SUCRA score (1.32%), reflecting minimal effectiveness. Conclusions: This study revealed PEA as a promising agent for long-term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy. The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long-term efficacy and safety for NTG.
Subjects
low tension glaucoma
network meta‐analysis
pharmaceutical preparations
systematic review
SDGs
Publisher
John Wiley and Sons Inc
Type
journal article